3rd Quarter - Report

HOLLAND & KNIGHT LLP for SHIRE PHARMACEUTICALS, INC

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug shortage legislation: Preserving Access to Life-Saving Medications Act (H.R. 2245 and S. 296); Drug Shortage Prevention Act of 2012 (H.R. 3839) to be sure companies in compliance with FDA/DEA rules were not penalized; legislative provisions concerning DEA quotas for controlled substances; manufacturing and distribution process regarding Adderall; dispensing of Adderall products. Lobbied for inclusion of provisions in S. 3187, the Food & Drug Administration Safety & Innovation Act and HR 5651, the Food & Drug Administration Reform Act of 2012. Also worked on provisions in those billes that: provide for accelerated approval, modify FDA Advisory Committee Rules, create a voucher program to incentivize companies to develop products for rare pediatric cancer, and extend enantiomer exclusivity program.

LobbyistCovered position, as disclosed
MICHAEL WERNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5651 (112th), S. 296 (112th), H.R. 3839 (112th), S. 3187 (112th), H.R. 2245 (112th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.